Indication
Post-menopausal osteoporosis prevention
Post-menopausal osteoporosis prevention refers to clinical and pharmacological interventions targeted at postmenopausal females to inhibit rapid bone loss and preserve skeletal microarchitecture. Read more about Post-menopausal osteoporosis prevention
352 drugs 122 manufacturers
Drugs that treat it
Common Post-menopausal osteoporosis prevention therapies.
ACTIVELLA (estradiol/norethindrone acetate)
RECLAST (zoledronic acid in mannitol and water for injection)
VIVELLE-DOT (estradiol)
ESTRADIOL (ONCE WEEKLY) (estradiol)
ESTRADIOL (TWICE WEEKLY) (estradiol)
RALOXIFENE HCL
ESTRADIOL
RALOXIFENE HCL
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPost-menopausal osteoporosis prevention refers to clinical and pharmacological interventions targeted at postmenopausal females to inhibit rapid bone loss and preserve skeletal microarchitecture.
This clinical indication addresses the skeletal consequences of natural or surgical menopause, where ovarian estrogen deficiency disrupts normal bone remodeling by accelerating osteoclast-mediated bone resorption beyond osteoblast-mediated bone formation.
The resulting uncoupled turnover leads to progressive loss of bone mineral density, architectural deterioration of trabecular and cortical bone, and increased susceptibility to low-trauma fragility fractures.
Preventative therapy is aimed at sustaining bone mass and maintaining bone quality before clinical osteoporosis or osteoporotic fractures develop.
- nih.gov
Post-menopausal osteoporosis prevention refers to clinical and pharmacological interventions targeted at postmenopausal females to inhibit rapid bone loss and preserve skeletal microarchitecture This clinical indication addresses the skeletal consequences of natural or surgical menopause, where ovarian estrogen deficiency disrupts normal bone remodeling by accelerating osteoclast-mediated bone resorption beyond osteoblast-mediated bone formation The resulting uncoupled turnover leads to progress...
- nih.gov
Post-menopausal osteoporosis prevention refers to clinical and pharmacological interventions targeted at postmenopausal females to inhibit rapid bone loss and preserve skeletal microarchitecture The resulting uncoupled turnover leads to progressive loss of bone mineral density, architectural deterioration of trabecular and cortical bone, and increased susceptibility to low-trauma fragility fractures
- nih.gov
This clinical indication addresses the skeletal consequences of natural or surgical menopause, where ovarian estrogen deficiency disrupts normal bone remodeling by accelerating osteoclast-mediated bone resorption beyond osteoblast-mediated bone formation
- nih.gov
The resulting uncoupled turnover leads to progressive loss of bone mineral density, architectural deterioration of trabecular and cortical bone, and increased susceptibility to low-trauma fragility fractures Preventative therapy is aimed at sustaining bone mass and maintaining bone quality before clinical osteoporosis or osteoporotic fractures develop
- nih.gov
Preventative therapy is aimed at sustaining bone mass and maintaining bone quality before clinical osteoporosis or osteoporotic fractures develop
Personalize your experience
Follow Post-menopausal osteoporosis prevention and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.